Chief Commercial Officer at Sofgen Pharma (PRCWF) named reporting insider in Form 3

Rhea-AI Filing Summary

Sofgen Pharma S.A. filed an initial Form 3 for Chief Commercial Officer Luis Alberto Palacios. This filing identifies him as an officer and reporting person for Sofgen Pharma’s securities but does not report any transactions or derivative positions. It establishes his status for future ownership disclosures.

Key Figures

Buy transactions: 0 Sell transactions: 0 Derivative transactions: 0 +1 more

4 metrics

Buy transactions 0 Form 3 transaction summary

Sell transactions 0 Form 3 transaction summary

Derivative transactions 0 Form 3 derivativeTransactionCount

Exercise transactions 0 Form 3 exerciseCount

Key Terms

Form 3, reportingPersons, Chief Commercial Officer, transactionSummary

4 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reportingPersons regulatory

""reportingPersons": [ { "name": "Palacios Luis Alberto""

Chief Commercial Officer financial

""officer_title": "Chief Commercial Officer""

A chief commercial officer (CCO) is the senior executive responsible for a company’s revenue-generating activities, including sales, marketing, pricing, customer relationships and business development. Think of the CCO as the head coach who builds the game plan to win customers and grow sales; their effectiveness affects how fast a company earns money, enters new markets and sustains profits, making the role a key signal for investors about future revenue and competitive strength.

transactionSummary regulatory

""transactionSummary": { "buyCount": 0, "sellCount": 0"

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Palacios Luis Alberto

(Last) (First) (Middle)

11600 MIRAMAR PARKWAY, SUITE 300

(Street)

MIRAMAR 33025

(City) (State) (Zip)

COLOMBIA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Sofgen Pharma S.A. [ PROC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

See Exhibit 24 - Power of Attorney.

No securities are beneficially owned.

	/s/ Freddy Andres Lozano Reyes, attorney-in-fact	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Sofgen Pharma (PRCWF) Form 3 for Luis Alberto Palacios show?

The Form 3 registers Luis Alberto Palacios, Sofgen Pharma’s Chief Commercial Officer, as a reporting person. It lists no buy, sell, or derivative transactions, serving mainly to establish his status for future ownership reporting obligations.

Does the Sofgen Pharma (PRCWF) Form 3 report any insider trades?

No insider trades are reported in this Form 3. The transaction summary shows zero buys, zero sells, and no derivative exercises, indicating the filing is purely an initial ownership registration for the Chief Commercial Officer.

Who is the reporting person in the Sofgen Pharma (PRCWF) Form 3 filing?

The reporting person is Luis Alberto Palacios, who serves as Chief Commercial Officer of Sofgen Pharma S.A. The filing designates him as an officer subject to ongoing insider reporting rules for the company’s securities.

Are any derivative securities disclosed in this Sofgen Pharma (PRCWF) Form 3?

No derivative securities are disclosed. The derivative summary is empty and derivativeTransactionCount is zero, indicating no options, warrants, or other derivative positions are reported in this initial Form 3 for the officer.

Why is a Form 3 important for Sofgen Pharma (PRCWF) insiders like the CCO?

Form 3 is the initial beneficial ownership statement for company insiders. By filing it for the Chief Commercial Officer, Sofgen Pharma ensures future trades or holdings changes can be tracked through subsequent Forms 4 or 5 under SEC rules.